185 related articles for article (PubMed ID: 10873024)
1. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2.
Alavi K; Schwartz MZ; Palazzo JP; Prasad R
J Pediatr Surg; 2000 Jun; 35(6):847-51. PubMed ID: 10873024
[TBL] [Abstract][Full Text] [Related]
2. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease.
Peterson RL; Wang L; Albert L; Keith JC; Dorner AJ
Lab Invest; 1998 Dec; 78(12):1503-12. PubMed ID: 9881950
[TBL] [Abstract][Full Text] [Related]
3. Growth factor manipulation of intestinal angiogenesis: a possible new paradigm in the management of inflammatory bowel disease.
Thatch KA; Mendelson KG; Haber MM; Schwartz MZ
J Surg Res; 2009 Oct; 156(2):245-9. PubMed ID: 19524260
[TBL] [Abstract][Full Text] [Related]
4. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.
Bertrand V; Quéré S; Guimbaud R; Sogni P; Chauvelot-Moachon L; Tulliez M; Lamarque D; Charreire J; Giroud JP; Couturier D; Chaussade S; Breban M
Eur Cytokine Netw; 1998 Jun; 9(2):161-70. PubMed ID: 9681392
[TBL] [Abstract][Full Text] [Related]
5. Measurement of cytokine mRNA expression in intestinal biopsies of cats with inflammatory enteropathy using quantitative real-time RT-PCR.
Nguyen Van N; Taglinger K; Helps CR; Tasker S; Gruffydd-Jones TJ; Day MJ
Vet Immunol Immunopathol; 2006 Oct; 113(3-4):404-14. PubMed ID: 16879876
[TBL] [Abstract][Full Text] [Related]
6. GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion.
Prasad R; Alavi K; Schwartz MZ
J Pediatr Surg; 2001 Apr; 36(4):570-2. PubMed ID: 11283879
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model.
Bowen-Yacyshyn MB; Bennett CF; Nation N; Rayner D; Yacyshyn BR
J Pharmacol Exp Ther; 2002 Sep; 302(3):908-17. PubMed ID: 12183646
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.
Martin GR; Wallace LE; Sigalet DL
Am J Physiol Gastrointest Liver Physiol; 2004 Jun; 286(6):G964-72. PubMed ID: 14962847
[TBL] [Abstract][Full Text] [Related]
9. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease.
Arthur GL; Schwartz MZ; Kuenzler KA; Birbe R
J Pediatr Surg; 2004 Mar; 39(3):448-52; discussion 448-52. PubMed ID: 15017568
[TBL] [Abstract][Full Text] [Related]
10. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
Dubé PE; Forse CL; Bahrami J; Brubaker PL
Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
[TBL] [Abstract][Full Text] [Related]
11. Up-regulated intragraft gene expression, ICAM-1 and IL-2R molecules, and apoptotic epithelial cells during rejection of rat small intestine allografts.
Li Y; Li N; Li Y; Wu B; Li J
Chin Med J (Engl); 2001 Oct; 114(10):1089-94. PubMed ID: 11677773
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2.
Ivory CP; Wallace LE; McCafferty DM; Sigalet DL
Am J Physiol Gastrointest Liver Physiol; 2008 Dec; 295(6):G1202-10. PubMed ID: 18845573
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect.
Bulut K; Meier JJ; Ansorge N; Felderbauer P; Schmitz F; Hoffmann P; Schmidt WE; Gallwitz B
Regul Pept; 2004 Sep; 121(1-3):137-43. PubMed ID: 15256284
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
15. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.
Thulesen J; Hartmann B; Hare KJ; Kissow H; Ørskov C; Holst JJ; Poulsen SS
Gut; 2004 Aug; 53(8):1145-50. PubMed ID: 15247183
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
Siddique I; Hasan F; Khan I
Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease.
Peterson RL; Wang L; Albert L; Marchese E; Erickson J; Wong A; Mounts WM; Hayes L; Bouchard P; Keith J; Dorner AJ
Pharmacogenomics J; 2002; 2(6):383-99. PubMed ID: 12629504
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression.
Taurog JD; Maika SD; Simmons WA; Breban M; Hammer RE
J Immunol; 1993 May; 150(9):4168-78. PubMed ID: 8473755
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis.
L'Heureux MC; Brubaker PL
J Pharmacol Exp Ther; 2003 Jul; 306(1):347-54. PubMed ID: 12815012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
